Previous studies have shown that high expression of DTYMK in HCC is associated with poor prognosis, and HCC cell lines with elevated DTYMK expression showed increased sensitivity to multiple chemotherapy agents such as sorafenib [50]. The gene discussed is DTYMK; the disease is hepatocellular carcinoma.